Court dismisses Novartis challenge to Indian patent law

Indian Pharmaceutical Patent Law and the Effects of Novartis Ag v. Union of India

Indian Patent Law On Biotechnological Inventions

APBN • Vol. 4 • No. 4 • 2000 79 Provisions of the Patents Act, 1970 Unlike the patent laws of most developed and even some developing countries, the current patent law in India, viz. the Patents Act, 1970, does not explicitly exclude or include any biological matter. For instance, the European Patent Convention explicitly excludes the patenting of plant and animal varieties and essentially biol...

How Much Has the Supreme Court Changed Patent Law

How Can the Supreme Court Not “Understand” Patent Law?

The Supreme Court does understand patent law. This invited Essay responds to Federal Circuit Judge Dyk’s remarks at the Chicago-Kent Supreme Court IP Review, in particular, his observation that the patent “bar and the academy have expressed skepticism that the Supreme Court understands patent law well enough to make the governing rules” (a view Judge Dyk did not endorse). The idea that the Supr...

“To patent or not to patent? the case of Novartis’ cancer drug Glivec in India”

BACKGROUND Glivec (imatinib mesylate), produced by the pharmaceutical company Novartis, is prescribed in the case of chronic myeloid leukemia, one of the most common blood cancers in eastern countries. After more than a decade of legal battles surrounding its patentability, the Supreme Court of India gave its final decision on April 1st of 2013, rejecting the appeal of the Swiss giant drug manu...